References
- Abubakar MB, Sanusi KO, Ugusman A, Mohamed W, Kamal H, Ibrahim NH, Khoo CS, Kumar J. 2022. Alzheimer’s disease: an update and insights into pathophysiology [Review]. Front Aging Neurosci. 1–14.
- Dhivya LS, Pradeepa BR, Sarvesh S. 2022. Synthesis and in vitro studies for structure-based design of novel chalcones as antitubercular agents targeting InhA. Future Med Chem. 14(12):851–866. doi: 10.4155/fmc-2022-0052.
- Durg S, Veerapur VP, Neelima S, Dhadde SB. 2017. Antidiabetic activity of Embelia ribes, embelin and its derivatives: a systematic review and meta-analysis. Biomed Pharmacother. 86:195–204. doi: 10.1016/j.biopha.2016.12.001.
- Li FS, Weng JK. 2017. Demystifying traditional herbal medicine with modern approach. Nat Plants. 3(8):17109. doi: 10.1038/nplants.2017.109.
- Nuthakki VK, Sharma A, Kumar A, Bharate SB. 2019. Identification of embelin, a 3-undecyl-1,4-benzoquinone from Embelia ribes as a multitargeted anti-Alzheimer agent. Drug Dev Res. 80(5):655–665. doi: 10.1002/ddr.21544.
- Prasathkumar M, Anisha S, Dhrisya C, Becky R, Sadhasivam S. 2021. Therapeutic and pharmacological efficacy of selective Indian medicinal plants – A review. Phytomedicine Plus. 1(2):100029. doi: 10.1016/j.phyplu.2021.100029.
- Preethi L, Ganamurali N, Dhanasekaran D, Sabarathinam S. 2021. Therapeutic use of Guggulsterone in COVID-19 induced obesity (COVIBESITY) and significant role in immunomodulatory effect. Obes Med. 24:100346. doi: 10.1016/j.obmed.2021.100346.
- Priya SS, Jha A, Satish Kumar RC, Sabarathinam S. 2022. The role of guggulsterone on the NF-κB pathway in inflammatory bowel disease: preclinical evidence. Future Sci OA. 8(6):Fso803. doi: 10.2144/fsoa-2022-0020.
- Sabarathinam S, Rajappan Chandra SK, Satheesh S. 2023. Network pharmacology based pharmacokinetic assessment and evaluation of the therapeutic potential of catechin derivatives as a potential myostatin inhibitor: a special view on Sarcopenic Obesity. Nat Prod Res. 37:1–5. doi: 10.1080/14786419.2023.2191197.
- Sabarathinam S, Vijayakumar TM. 2021a. Assessment of herb-drug interactions based on the pharmacokinetic changes of probe drug, midazolam. Drug Metab Lett. 14(1):5–8. doi: 10.2174/1872312814666201112122110.
- Sabarathinam S, Vijayakumar TM. 2021b. A short exploration of selected sensitive CYP3A4 substrates (probe drug). Drug Metab Lett. 14(1):2–4. doi: 10.2174/1872312814666200811110024.
- Sharma V, Gautam DNS, Radu AF, Behl T, Bungau SG, Vesa CM. 2022. Reviewing the traditional/modern uses, phytochemistry, essential oils/extracts and pharmacology of embelia ribes burm. Antioxidants (Basel). 11(7):1–10. doi: 10.3390/antiox11071359.
- Vaithiyalingam M, Sumathi DL, Sabarathinam S. 2023. Isolation and in silico study of curcumin from curcuma longa and its anti-diabetic activity. Appl Biochem Biotechnol. 195(2):947–957. doi: 10.1007/s12010-022-04173-3.